Renaissance of targeting molecules for melanoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 6, 2006, Pages 545-552

  Dadachova, Ekaterina ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antimelanin antibodies; Melanin; Melanoma; Radioimmunotherapy; Radiolabeled peptides; Surface antigens

Indexed keywords

BISMUTH 213; GANGLIOSIDE GD3; HISTIDYLTYROSYLASPARAGINYLISOLEUCYLCYSTEINE 4B4 RE 188; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT I 131; INTERMEDIN DERIVATIVE; MELANIN; MELANOMA ANTIGEN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6D2 RE 188; MONOCLONAL ANTIBODY 9.2.27 BI 213; MONOCLONAL ANTIBODY KM871 IN 111; MONOCLONAL ANTIBODY ZME 018 IN 111; MONOCLONAL ANTIBODY ZME 018 Y 90; PEPTIDE DERIVATIVE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; ISOTOPE LABELING; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RADIOIMMUNOTHERAPY; TREATMENT INDICATION; UNITED STATES;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MELANINS; MELANOCYTE-STIMULATING HORMONES; MELANOMA; NEOPLASM METASTASIS; RADIOIMMUNOTHERAPY;

EID: 33846633608     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.545     Document Type: Article

References (38)

1. Safa MM, Foon KA. Adjuvant immunotherapy for melanoma and colorectal cancers. Semin Oncol 2001; 28:68.
2. Sun W, Schuchter LM. Metastatic melanoma. Curr Treat Options Oncol 2001;1:193.
3. DeNardo SJ, Erickson KL, Benjamin E, et al. Radioimmunotherapy for melanoma. Clin Res 1981; 29:434.
4. Larson SM, Carrasquillo JA, McGuffin RW, et al. Use of I-131 labeled, murine Fab against a high-molecular-weight antigen of human melanoma: Preliminary experience. Radiology 1985;155:487.
5. DeNardo GL. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med 2005;35:202.
6. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441.
7. DeNardo SJ, Hines HH, Erickson KL et al. The evaluation of radiolabeled monoclonal antibody parameters necessary for cancer immunotherapy. In: Chabner BA, ed., Rational Basis for Chemotherapy. New York: Alan R. Liss, Inc., 1983:379.
8. DeNardo SJ, GL DeNardo, J-S Peng, et al. Monoclonal antibody radiopharmaceuticals for cancer radioimmunotherapy. In: Burchiel S, Rhodes, B, eds., Radioimmunoimaging and Radioimmunotherapy. Elsevier Publisheing Co., Inc., New York.
9. Imai K, Wilson BS, Bigotti A, et al. A 94,000-Dalton glycoprotein expressed by human melanoma and carcinoma cells. JNCI 1982;68:761.
10. Brown JP, Nishiyama K, Hellstrom I, et al. Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies. J Immunol 1981;127:539.
11. Buraggi GL. Radioimmunodetection of malignant melanoma with the 225.28S monoclonal antibody to HMW-MAA. Nucl Med 1986;25:220.
12. Kang NV, Yong A. New techniques for imaging metastatic melanoma. Surgery (St. Louis) 1998;16:5.
13. Rofstad EK. Radiation biology of malignant melanoma. Acta Radiol Oncol 1986;25:1.
14. Rofstad EK, Mathiesen B, Galappathi K. Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: Radiation-induced increase in fraction of hypoxic cells and hypoxia-induced upregulation of urokinase-type plasminogen activator receptor. Cancer Res 2004;64:13.
15. Taylor A, Jr, Milton W, Eyre HP, et al. Radioimmunodetection of human melanoma with indium-111-labeled monoclonal antibody. J Nucl Med 1988;29:329.
16. Milenic DE. Radioimmunotherapy: Designer molecules to potentiate effective therapy. Semin Radiat Oncol 2000;10:139.
17. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004;3:488.
18. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46(Suppl. 1):115S.
19. Murtha AD. Review of low-dose-rate radiobiology for clinicians. Semin Radiat Oncol 2000;10:133.
20. Knox SJ, Goris ML, Wessels BW. Overview of animal studies comparing radioimmunotherapy with dose-equivalent external beam radiation. Radiother Oncol 1992;23:111.
21. Xue LY, Butler NJ, Makrigiorgos GM, et al. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci USA 2002;99:13765.
22. Macklis RM. How and why does radioimmunotherapy work? Int J Radiation Oncology Biol Phys 2004;59:1269.
23. Scott AM, Lee FT, Hopkins W, et al. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: Results of a phase I trial. J Clin Oncol 2001;19:3976.
24. Urbano N, Papi S, Ginanneschi M, et al. Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT). Eur J Nucl Med Mol Imaging 2007;34:68.
25. Allen BJ, Raja C, Rizvi S, et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2005;4:1318.
26. Dadachova E, Nosanchuk JD, Shi L, et al. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin. Proc Natl Acad Sci USA 2004;101:14865.
27. Rosas AL, Nosanchuk JD, Feldmesser M, et al. Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect Immun 2000; 68:2845.
28. Wakamatsu K, Ito S. Advanced chemical methods in melanin determination. Pigment Cell Res 2002;15:174.
29. Matzku S, Kirchgessner H, Schmid U, et al. Melanoma targeting with a cocktail of monoclonal antibodies to distinct determinants of the human HMW-MAA. J Nucl Med 1989;30:390.
30. Schweitzer AD, Rakesh V, Revskaya E, et al. Finite element-based computational modeling of radioactivity delivery to a tumor by a radiolabeled melanin-binding antibody. J Nucl Med 2006;47(Suppl. 1):200P.
31. Krenning EP, Kwekkeboom DJ, Valkema R, et al. Peptide receptor radionuclide therapy. Ann NY Acad Sci 2004;1014:234.
32. Blok D, Feitsma RI, Vermeij P, et al. Peptide radiopharmaceuticals in nuclear medicine. Eur J Nucl Med 1999;26:1511.
33. Miao Y, Whitener D, Feng W, et al. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem 2003;4:1177.
34. Cheng Z, Chen J, Quinn TP, et al. Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res 2004;64:1411.
35. 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med 2005;46:121.
36. Rogers DC, Fisher EM, Brown SD, et al. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm Genome 1997;8:711.
37. Dadachova E, Moadel T, Schweitzer AD, et al. Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease. Cancer Biother Radiopharm 2006; 21:117.
38. Dadachova E, Casadevall A. Melanin as a potential target for radionuclide therapy of metastatic melanoma. Future Oncol 2005;1:541.